Financials ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-12-01 pm EST Intraday chart for ICON Public Limited Company 5-day change 1st Jan Change
269.35 USD +0.90% -0.93% +38.66%

Valuation

Fiscal Period : December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 7 034 9 239 10 290 25 209 15 860 22 175 - -
Enterprise Value (EV) 1 6 927 9 018 9 797 29 891 20 223 25 559 24 576 23 505
P/E ratio 21,9x 25,4x 31,7x 138x 31,7x 39,8x 29,0x 23,4x
Yield - - - - - - - -
Capitalization / Revenue 2,71x 3,29x 3,68x 4,60x 2,05x 2,72x 2,55x 2,37x
EV / Revenue 2,67x 3,21x 3,50x 5,45x 2,61x 3,14x 2,82x 2,52x
EV / EBITDA 15,3x 18,2x 20,6x 30,8x 13,7x 15,2x 13,4x 11,8x
EV / FCF 31,5x 24,9x 19,0x 40,6x 48,0x 23,8x 19,7x 16,5x
FCF Yield 3,18% 4,01% 5,28% 2,46% 2,08% 4,21% 5,08% 6,06%
Price to Book 5,23x 5,71x 5,56x 3,13x 1,87x 2,42x 2,19x 1,96x
Nbr of stocks (in thousands) 54 436 53 641 52 775 81 398 81 645 82 327 - -
Reference price 2 129 172 195 310 194 269 269 269
Announcement Date 20/02/19 19/02/20 24/02/21 22/02/22 22/02/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period : December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 2 596 2 806 2 797 5 481 7 741 8 147 8 710 9 342
EBITDA 1 452 495 476 970 1 479 1 684 1 832 1 998
EBIT 1 386 433 410 655 1 373 1 562 1 695 1 850
Operating Margin 14,9% 15,4% 14,6% 12,0% 17,7% 19,2% 19,5% 19,8%
Earnings before Tax (EBT) 1 365 427 381 197 568 642 867 1 067
Net income 1 323 374 332 153 505 554 761 958
Net margin 12,4% 13,3% 11,9% 2,79% 6,53% 6,80% 8,74% 10,3%
EPS 2 5,89 6,79 6,15 2,25 6,13 6,77 9,28 11,5
Free Cash Flow 1 220 362 517 735 421 1 076 1 248 1 425
FCF margin 8,48% 12,9% 18,5% 13,4% 5,44% 13,2% 14,3% 15,3%
FCF Conversion (EBITDA) 48,8% 73,1% 109% 75,8% 28,5% 63,9% 68,1% 71,3%
FCF Conversion (Net income) 68,3% 96,8% 156% 480% 83,3% 194% 164% 149%
Dividend per Share 2 - - - - - - - -
Announcement Date 20/02/19 19/02/20 24/02/21 22/02/22 22/02/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period : December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 871 1 866 1 885 1 902 1 935 1 942 1 962 1 979 2 020 2 055 2 093 2 107 2 152 2 201 2 240
EBITDA 1 150 325 333 341 354 380 405 399 414 433 440 436 449 464 473
EBIT 1 133 214 193 314 329 353 378 254 209 401 408 403 418 430 439
Operating Margin 15,3% 11,4% 10,2% 16,5% 17,0% 18,2% 19,3% 12,8% 10,4% 19,5% 19,5% 19,1% 19,4% 19,6% 19,6%
Earnings before Tax (EBT) 1 88,5 -97,1 91,8 126 131 182 129 131 125 182 214 211 228 251 269
Net income 1 73,9 -94,3 76,5 112 116 160 117 117 116 164 172 176 194 212 225
Net margin 8,48% -5,05% 4,06% 5,89% 5,98% 8,25% 5,99% 5,90% 5,72% 7,96% 8,22% 8,33% 9,01% 9,62% 10,0%
EPS 2 1,38 -1,17 0,92 1,36 1,41 1,94 1,42 1,41 1,40 1,97 2,11 2,10 2,34 2,55 2,69
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 07/21/21 11/03/21 02/22/22 04/27/22 07/27/22 11/02/22 02/22/23 04/26/23 07/26/23 10/25/23 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period : December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - 4 682 4 364 3 384 2 401 1 330
Net Cash position 1 106 220 494 - - - - -
Leverage (Debt/EBITDA) - - - 4,83x 2,95x 2,01x 1,31x 0,67x
Free Cash Flow 1 220 362 517 735 421 1 076 1 248 1 425
ROE (net income / shareholders' equity) 26,2% 25,2% 19,2% 13,4% 11,7% 11,8% 12,7% 13,0%
Shareholders' equity 1 1 231 1 486 1 735 1 140 4 320 4 706 5 983 7 343
ROA (Net income/ Total Assets) 14,8% 14,2% 10,5% 6,40% 5,60% 5,80% 6,51% 7,19%
Assets 1 2 176 2 631 3 171 2 394 9 017 9 559 11 685 13 327
Book Value Per Share 2 24,7 30,2 35,1 98,9 104 111 123 138
Cash Flow per Share 2 4,90 7,59 10,7 12,4 6,83 14,0 16,3 17,6
Capex 1 48,4 50,6 51,1 93,8 142 150 165 183
Capex / Sales 1,86% 1,80% 1,83% 1,71% 1,84% 1,84% 1,90% 1,96%
Announcement Date 02/20/19 02/19/20 02/24/21 02/22/22 02/22/23 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
269.35USD
Average target price
285.14USD
Spread / Average Target
+5.86%
Consensus
  1. Stock
  2. Equities
  3. Stock ICON Public Limited Company - Nasdaq
  4. Financials ICON Public Limited Company
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer